IVERIC bio Investor Relations Material
Latest events
Q4 2022
IVERIC bio
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from IVERIC bio Inc
Access all reports
IVERIC bio, Inc. is a biopharmaceutical company specializing in the discovery and development of treatments for retinal diseases. The company's focus includes developing therapies for age-related macular degeneration and other ocular conditions that lead to vision loss. IVERIC bio aims to address unmet medical needs in ophthalmology through innovative research and targeted approaches to eye health. The company is headquartered in Parsippany, New Jersey, and its shares are listed on the NASDAQ.
Latest articles
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
Ticker symbol
ISEE
Country
🇺🇸 United States